Dr. Zervas has developed novel models to interrogate neurological disorders including: Human iPSC (hiPSC)-derived excitatory neurons to evaluate novel targets identified via human transcriptomics to assess PTSD biology and evaluate putative therapeutics to correct aberrant PTSD phenotypes (manuscript under revision at Frontiers in Drug Discovery. Additionally, he developed a novel platform that merged hiPSC-derived neural circuitry, hiPSC-derived blood brain barrier cells, hiPSC-derived astrocytes, and hiPSC-derived microglia to evaluate therapeutics designed to correct BBB dysfunction subsequent to Traumatic Brain Injury. Additional in vitro models include using hiPSC-derived dopamine neurons to test early stage therapeutics to correct mitochondrial dysfunction, developing mouse embryonic stem cell lines to ascertain molecular programming of VTA dopamine neurons, developing in vitro system using ferret cortical neurons to determine how inhibiting ganglioside synthesis impacts the establishment of basilar dendrites.